Medical Science Liaison, Rare Neurology, Eastern PA/Upstate NY
Alexion Pharmaceuticals, Inc.
Summary
The Medical Science Liaison (MSL) is a field-based scientific expert that strategically supports the medical and scientific objectives of Alexion, AstraZeneca Rare Disease's product/s across the product/s life cycle. The individual is a peer scientific expert who communicates accurate and applicable science to Healthcare Practitioners (HCPs) within a geographic area. The individual manages and maintains collegial and professional relationships with HCPs and Key Opinion Leaders (KOLs) and identifies and facilitates collaboration opportunities with Alexion, AstraZeneca Rare Disease. The MSL combines strong business acumen and clinical expertise and serves as a peer-to-peer liaison internally to Medical Directors, USMA Leadership Team, cross-functional partners and externally (HCPs & KOLs).
Job description
You Will Be Responsible For
HCP relationship management
- Evaluates their territory to profile and identify the HCPs to engage and build relationships with, as well as identify, important centers of excellence
- Develops clear, succinct, impactful HCP engagement plans, aligned with medical strategic goals and objectives. Evaluates and refines plans as needed per the progress against the quarterly focus priorities
- Gains HCPs' trust and respect by effectively providing and communicating relevant scientific/medical information on the company's products and disease states
- Gathers and disseminates HCP insights as appropriate internally to help inform medical strategy
- Develops strong working relationships in different external business settings
Scientific knowledge and training
- Keeps current with scientific knowledge within assigned products and therapeutic area
- Supports scientific exchange of product/disease state with external stakeholders (HCPs) as needed
- Provides relevant scientific information to other internal teams and functions as appropriate
- Demonstrates a functional understanding of real-world evidence and HEOR
Research & Development
- Demonstrates a strong understanding of clinical study design and protocols
- Ensures HCPs and stakeholders receive focused and balanced clinical and scientific information
- Develops expertise in applicable research outcomes to credibly conduct effective discussion with HCPs
- Supports applicable externally sponsored research and clinical trials, as appropriate
US Healthcare system knowledge
- Acquires knowledge of the current US healthcare system environment and its impact on the rare disease ecosystem
- Builds a basic understanding of the foundations of managed markets
- Acquires a basic understanding of the flow of information in managed care and government organizations
Requirements
- Bachelor's Degree
- 2+ years of direct patient care experience
- Clinical experience in a relevant therapeutic area OR track record of success as an MSL
- Excellent communication skills (oral and written)
- Strong personal initiative
- Functions well as part of a cross-functional team
- Excellent time management
- Able to work independently
- Demonstrates leadership skills and high-level job competencies
- Candidate is required to live within the territory
- Valid driver's license and clean driving record required
- Ability to travel minimum ~70% time
Benefits
- 401(k) Retirement Programs
- Paid Time Off
- Health Insurance
- Dental Insurance
- Vision Coverage
- Short-Term Incentive Bonuses
- Equity-Based Awards
Company overview
Alexion Pharmaceuticals, Inc., now a subsidiary of AstraZeneca, is a leading pharmaceutical company specializing in the development and commercialization of orphan drugs for rare diseases. Founded in 1992 and headquartered in Boston, Massachusetts, the company has established itself as a pioneer in treating ultra-rare disorders through innovative biologic therapies. Alexion's flagship products include Soliris (eculizumab) and Ultomiris (ravulizumab), both used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The company's portfolio also features Strensiq (asfotase alfa) for hypophosphatasia, Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency, and Andexxa (andexanet alfa) for reversing anticoagulation effects. With approximately 2,525 employees and annual revenues exceeding $6 billion, Alexion operates globally, focusing on life-transforming treatments for patients with severe and life-threatening rare diseases. The company's acquisition by AstraZeneca in 2021 has further strengthened its position in the rare disease therapeutic area, combining Alexion's specialized expertise with AstraZeneca's global reach and research capabilities.